The goal of this phase 2 study is to see whether the study drug might delay PD by modifying the activity of a gene involved in PD called GBA1. You may be eligible to participate if you are between the ages of 30 and 80 years old, have had between 1 and 7 years of Parkinson’s disease symptoms, are able to walk without assistance, and are taking medication for Parkinson’s disease.